Environmental modulation of atherosclerosis end points in familial hypercholesterolemia

Atherosclerosis Supplements

Volumn 2, Issue 3, 2002, Pages 5-7

  Hegele, Robert A ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL LIVER LEVEL; DISEASE SEVERITY; ENVIRONMENTAL CHANGE; ENVIRONMENTAL FACTOR; ENZYME DEFICIENCY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE EXPRESSION; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPODYSTROPHY; LONGEVITY; METABOLIC DISORDER; MONOGENIC DISORDER; MULTIFACTORIAL INHERITANCE; MULTIGENE FAMILY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ADULT; AGED; ARTERIOSCLEROSIS; BIOASSAY; CANADA; CHINA; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; ENVIRONMENT; ETHNOLOGY; FAT INTAKE; FEMALE; GENETIC PREDISPOSITION; GENETICS; HYPERLIPOPROTEINEMIA TYPE 2; MALE; MIDDLE AGED; ONSET AGE; REVIEW; RISK; UNITED STATES;

ADULT; AGE OF ONSET; AGED; ARTERIOSCLEROSIS; CANADA; CHINA; CORONARY ARTERIOSCLEROSIS; DIETARY FATS; DISEASE PROGRESSION; ENDPOINT DETERMINATION; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIFE STYLE; MALE; MIDDLE AGED; RECEPTORS, LDL; RISK; UTAH;

EID: 0036514388     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(01)00013-7     Document Type: Article

References (11)

1. Healthy people 2000: National health promotion and disease prevention objectives. US Department of Health and Human Services publication (PHS) 91-50212, Hyattsville MD, 1990.
2. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. 140:1998;199-270.
3. Hegele R.A. Candidate genes, small effects, and the prediction of atherosclerosis. Crit. Rev. Clin. Lab. Sci. 34:1997;343-367.
4. Cheng S., Pallaud C., Grow M.A., Scharf S.J., Erlich H.A., Klitz W., Pullinger C.R., Malloy M.J., Kane J.P., Siest G., Visvikis S. A multilocus genotyping assay for cardiovascular disease. Clin. Chem. Lab. Med. 36:1998;561-566.
5. Williams R.R., Hasstedt S.J., Wilson D.E., et al. Evidence that men with familial hypercholesterolemia can avoid early coronary death. An analysis of 77 gene carriers in four Utah pedigrees. J. Am. Med. Assoc. 255:1986;219-224.
6. Hegele R.A., Emi M., Wu L.L., Hopkins P.N., Williams R.R., Lalouel J.M. Clinical application of deoxyribonucleic acid markers in a Utah family with hypercholesterolemia. Am. J. Cardiol. 63:1989;109-112.
7. Pimstone S.N., Sun X.M., du Souich C., Frohlich J.J., Hayden M.R., Soutar A.K. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler. Thromb. Vasc. Biol. 18:1998;309-315.
8. Hegele R.A., Breckenridge W.C., Cox D.W., Maguire G.F., Little J.A., Connelly P.W. Interaction between variant apolipoproteins C-II and E that affects plasma lipoprotein concentrations. Arterioscler. Thromb. 11:1991;1303-1309.
9. Ng D.S., Leiter L.A., Vezina C., Connelly P.W., Hegele R.A. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J. Clin. Invest. 93:1994;223-229.
10. Hegele R.A., Cao H., Harris S.B., Hanley A.J., Zinman B. The hepatic nuclear factor-1alpha G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. J. Clin. Endocrinol. Metab. 84:1999;1077-1082.
11. Cao H., Hegele R.A. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum. Mol. Genet. 9:2000;109-112.